Short answer
MEN2A and MEN2B are both RET syndromes, but they do not behave the same way. MEN2A is the classic RET pattern associated with medullary thyroid cancer, pheochromocytoma, and sometimes parathyroid disease. MEN2B tends to bring earlier and more aggressive medullary thyroid cancer together with mucosal neuromas and a marfanoid body habitus.
That difference matters because the same positive RET result can lead to very different timing for thyroid care, adrenal screening, and family testing.
How they differ
| Pattern | MEN2A clue | MEN2B clue |
|---|---|---|
| Core syndrome | MTC, pheochromocytoma, possible parathyroid disease | Early aggressive MTC, pheochromocytoma, no clinically significant parathyroid disease |
| Physical clues | May be absent or subtle | Mucosal neuromas, thick lips, medullated corneal nerves, marfanoid habitus |
| Typical timing | Can vary widely by RET variant and family | Often very early childhood, with aggressive thyroid risk |
| Family action | Targeted RET testing and surveillance for affected relatives | Time-sensitive genetics and endocrine follow-up for relatives, often in childhood |
When MEN2A is more likely
MEN2A is more likely when medullary thyroid cancer, pheochromocytoma, or parathyroid disease is the main pattern and the family does not have the classic MEN2B physical findings. GeneReviews and NCI both emphasize that RET testing changes management because the phenotype can be highly variant-specific.
So MEN2A is often the result you think about when the endocrine pattern is broad but not obviously syndromic from appearance alone.
When MEN2B is more likely
MEN2B becomes more likely when medullary thyroid cancer shows up very early and there are mucosal neuromas, thickened lips, medullated corneal nerves, or a marfanoid habitus. GeneReviews says MEN2B should be suspected in people with those distinctive facial and mucosal findings, and NCI’s cancer terms also flag the syndrome as a RET-driven disorder with MTC and pheochromocytoma risk.
That is why MEN2B is often a time-sensitive diagnosis: the thyroid clock can be much faster.
When a negative result does not settle the question
A negative RET result does not always end the discussion if the phenotype is still convincing. The assay may not cover every relevant variant type, or the clinical picture may actually fit another hereditary PPGL syndrome better. SDHx genes, VHL, NF1, TMEM127, MAX, and EPAS1 can still explain the pheochromocytoma side of the picture.
That is why the exact variant call, the test methodology, and the family history still matter even after a report comes back.
Family testing and surveillance
If a pathogenic germline RET variant is confirmed, relatives may be offered targeted testing for the known family variant. The follow-up then usually focuses on the right thyroid timing first, with adrenal and calcium/parathyroid monitoring added as appropriate for the specific syndrome and variant.
In other words, MEN2 is not just a positive RET result. It is a timing and surveillance plan that needs to fit the exact RET syndrome.
Questions to ask
- What exact RET variant was found, and was it pathogenic, likely pathogenic, or uncertain?
- Does the family history look more like MEN2A or MEN2B?
- Was the result from germline testing, tumor-only testing, or consumer DNA data?
- Are calcitonin, thyroid ultrasound, calcium, parathyroid hormone, and metanephrines part of follow-up?
- Which relatives need targeted testing now?
- Does the child or adult need endocrinology plus genetics review without delay?
FAQ
What is the main difference between MEN2A and MEN2B?
Both are RET syndromes, but MEN2A is more associated with medullary thyroid cancer, pheochromocytoma, and sometimes parathyroid disease, while MEN2B is more associated with early aggressive medullary thyroid cancer, mucosal neuromas, and marfanoid features.
When is MEN2A more likely?
MEN2A is more likely when medullary thyroid cancer, pheochromocytoma, or parathyroid disease is the main pattern and the family history fits a RET syndrome without the classic MEN2B physical features.
When is MEN2B more likely?
MEN2B is more likely when medullary thyroid cancer appears very early and the person has mucosal neuromas, thickened lips, medullated corneal nerves, or a marfanoid habitus.
Does a negative RET result rule out MEN2?
No. A negative RET result does not fully settle the question if the clinical picture is still convincing, because test coverage, variant type, or interpretation issues may matter. A genetics specialist should review the exact assay and phenotype.
Should relatives be tested if one RET variant is positive?
Yes. First-degree relatives are often offered targeted testing for the known family variant, because that result can change thyroid and adrenal surveillance timing.
What follow-up tests matter after either result?
Calcitonin, thyroid ultrasound, calcium or parathyroid hormone, and metanephrines may all matter depending on the phenotype. The variant and the family pattern should guide follow-up, not the gene name alone.